DESTINY-Breast03 Phase 3 Study Results
Patient Characteristics
Patient Characteristcs
Sex; n (%)
Female
Male
|Age; median (range)
Age at Baseline
ECOG Performance Status; n (%)
ECOG O
N=15
14 (93.3%)
1 (6.7%)
69 (30-76)
9 (60%)
ECOG 1
6 (40%)
Presence of Neurologic Symptoms at Baseline; n (%)
Yes
6 (40%)
No
9 (60%)
Disease Subtype; n (%)
HER2-positive/Luminal B
12(80%)
HER2-positive/non-luminal
3 (20%)
Brain Metastases Free Survival (BMFS); median (range)
BMFS from Diagnosis of Metastatic Disease (months)
17 (0-48)
Visceral Metastases; n (%)
Yes
12 (80%)
No
3 (20%)
Prior HER2-directed Therapy; n (%)
Trastuzumab+Pertuzumab
T-DM1
15 (100%)
9 (60%)
Lapatinib
Other
Status of Brain Metastases; n (%)
Untreated
ESMO BC 2022 #165 Mini Oral
Progressive BM after prior Local Therapy
Prior Lines of Treatment for mBC; median (range)
Prior Lines of Treatment before T-DXd
4 (26.7%)
1 (6.7%)
6 (40%)
Daiichi-Sankyo
9 (60%)
2 (1-5)
54View entire presentation